New real world data show sofosbuvir/daclatasvir combination is an effective treatment option for difficult-to-treat hepatitis C patients

Study looks into further treatment option amongst hepatitis C virus genotype-1 mono-infected patients April 25, 2015, Vienna, Austria: Results presented today at The International Liver Congress™ 2015 show that the sofosbuvir (SOF)/daclatasvir (DCV) treatment combination is effective amongst hepatitis C virus (HCV) genotype-1 mono-infected patients. These results are significant because whilst other combinations have been … read more
Share this page: Share on TwitterShare on FacebookShare on LinkedIn+1Share via email

Researchers highlight need for better evidence to guide European efforts to increase hepatitis B and C testing

Review presented at The International Liver CongressTM 2015 documents lack of information about hepatitis B and C testing in many countries April 25, 2015, Vienna, Austria: The apparent dearth of research on hepatitis B and C testing in many European countries could be hampering efforts to identify infected individuals, according to results from a comprehensive … read more
Share this page: Share on TwitterShare on FacebookShare on LinkedIn+1Share via email

Sofosbuvir + peginterferon/ribavirin for 12 weeks demonstrates strongest sustained virologic response rates in genotype-3 hepatitis C patients

Results from the ground-breaking new BOSON study April 25, 2015, Vienna, Austria: Results presented today at The International Liver Congress™ 2015 demonstrate that hepatitis C (HCV)-infected genotype-3 (GT-3) patients, with and without cirrhosis, receiving 24 weeks of sofosbuvir (SOF) in combination with ribavirin (RBV) and peginterferon (PEG) achieved the highest sustained virologic response rates at … read more
Share this page: Share on TwitterShare on FacebookShare on LinkedIn+1Share via email

Alcohol use disorders are a stronger predictor of mortality than chronic hepatitis C virus infection in the general population

Chronic hepatitis C infection is associated with increased risk of mortality when severe comorbidities and/or alcohol use disorders are also present April 25, 2015, Vienna, Austria: Results presented today at The International Liver Congress™ 2015, show that alcohol use disorders (AUD) have a serious, negative prognostic outcome with higher mortality risks in the general population … read more
Share this page: Share on TwitterShare on FacebookShare on LinkedIn+1Share via email

Use of direct-antiviral agents helps overcome hepatitis C recurrence in liver transplant patients

New study showcases efficacy and safety of sofosbuvir and daclatasvir in patients with recurrent hepatitis C April 25, 2015, Vienna, Austria: New data presented today at The International Liver Congress™ 2015, supports the use of sofosbuvir (SOF)- and daclatasvir (DCV)-based regimens in patients with recurrence of the hepatitis C virus (HCV) following liver transplantation (LT). … read more
Share this page: Share on TwitterShare on FacebookShare on LinkedIn+1Share via email

Drinking just one or two alcoholic drinks a day linked to liver disease

New data highlights why reducing heavy drinking should be considered an important target for public health monitoring and policies April 25, 2015, Vienna, Austria: According to the World Health Organization, excessive alcohol drinking is the most common cause of cirrhosis worldwide. A new worldwide study presented at The International Liver Congress TM 2015 has shown … read more
Share this page: Share on TwitterShare on FacebookShare on LinkedIn+1Share via email

Use of pocket-sized ultrasound device helps reduce the need for further testing in a variety of clinical settings

Pocket-sized ultrasound device (PUD) use assists physicians in making more accurate diagnoses April 25, 2015, Vienna, Austria: Results from a study presented today at The International Liver Congress™ 2015 demonstrate that the use of a pocket-sized ultrasound device (PUD) helps to reduce the need for further testing in both the inpatient and outpatient setting. The … read more
Share this page: Share on TwitterShare on FacebookShare on LinkedIn+1Share via email

Hepatitis C screening essential to help catch patients with advanced liver fibrosis

Research validates the current recommendation that screening for hepatitis C, particularly among high-risk groups, is vital April 25, 2015, Vienna, Austria: Study results presented today at The International Liver Congress™ 2015 show that the occurrence of advanced liver fibrosis is similar for patients infected with the hepatitis C virus (HCV), whether or not they have … read more
Share this page: Share on TwitterShare on FacebookShare on LinkedIn+1Share via email

Daclatasvir, sofosbuvir and ribavirin combination is highly effective and well tolerated in hepatitis C patients with advanced cirrhosis or post-liver transplant recurrence

Results from ALLY-1 confirm combination addresses a high unmet therapeutic need for these patients April 25, 2015, Vienna , Austria: Phase 3 results presented today at The International Liver Congress™ 2015 show that a combination of daclatasvir (DCV), sofosbuvir (SOF) and ribavirin (RBV) for 12 weeks was effective and well tolerated amongst patients with hepatitis … read more
Share this page: Share on TwitterShare on FacebookShare on LinkedIn+1Share via email

Preliminary findings suggest interferon-free direct-acting antiviral combination is well tolerated in patients with chronic hepatitis C and severe renal impairment or end-stage renal disease

Safety findings from the ongoing RUBY-1 study evaluating ombitasvir / paritaprevir / ritonavir in combination with dasabuvir (3D) in chronic hepatitis C virus (HCV) genotype 1 (GT1) patients with severe renal impairment or end-stage renal disease April 25, 2015, Vienna, Austria: Preliminary data from an ongoing study revealed today at The International Liver Congress™ 2015 … read more
Share this page: Share on TwitterShare on FacebookShare on LinkedIn+1Share via email

Novel therapeutic candidate targets key driver of hepatocellular carcinoma in genomically defined subset of patients

Preclinical data demonstrate that BLU-554 is first potent and selective FGFR4 inhibitor April 24, 2015, Vienna, Austria: Findings were presented today at The International Liver CongressTM 2015 on a novel therapeutic candidate for a genomically defined subset of hepatocellular carcinoma (HCC) patients with an aberrant fibroblast growth factor receptor 4 (FGFR4) pathway. BLU-554, a small … read more
Share this page: Share on TwitterShare on FacebookShare on LinkedIn+1Share via email

Once-daily grazoprevir/elbasvir is effective and well-tolerated in patients infected with chronic hepatitis C virus

Positive results from the Phase 3 C-EDGE TN study in treatment-naive patients April 24, 2015, Vienna, Austria: Results presented today at The International Liver Congress™ 2015 show that a 12-week oral regimen of once-daily single tablet grazoprevir/elbasvir (GZR/EBR) is effective and well-tolerated in treatment-naive (TN) patients infected with chronic hepatitis C virus (HCV) genotypes (GT)-1, … read more
Share this page: Share on TwitterShare on FacebookShare on LinkedIn+1Share via email

Non-alcoholic steatohepatitis associated with a 50% higher chance of death compared with non-alcoholic fatty liver disease

Large population-based cohort provides important new insights into mortality and cardiovascular disease over the non-alcoholic fatty liver disease spectrum April 24, 2015, Vienna, Austria: Results from a large population-based cohort of almost a million people in the UK found that the chances of dying from non-alcoholic steatohepatitis (NASH), over a 14-year period, was approximately 50% … read more
Share this page: Share on TwitterShare on FacebookShare on LinkedIn+1Share via email

Ledipasvir-sofosbuvir combination proves highly effective in subset of patients with chronic hepatitis C

Simple, ribavirin- and interferon-free, all-oral regimen provides new treatment option for people with hepatitis C, genotypes 4 and 5 April 24, 2015, Vienna, Austria: A new study presented today at The International Liver Congress™ 2015 has demonstrated that ledipasvir (LDV) in combination with sofosbuvir (SOF) achieves sustained virologic response rates 12 weeks after treatment (SVR12; … read more
Share this page: Share on TwitterShare on FacebookShare on LinkedIn+1Share via email

Investigational anti-diabetic compound may offer potential for management of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis

Remogliflozin etabonate shown to reverse insulin resistance and provide anti-oxidant activity April 23, 2015, Vienna, Austria: Data presented today at The International Liver Congress™ 2015 demonstrates that remogliflozin etabonate, an investigational drug in type 2 diabetes, is a potential treatment option for the management of patients with non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease … read more
Share this page: Share on TwitterShare on FacebookShare on LinkedIn+1Share via email

Genomic analyses point to the potential of personalised care for liver cancer patients

Use of exome sequencing helps determine which hepatocellular carcinoma patients could benefit from targeted anticancer treatments April 23, 2015, Vienna, Austria: A new study presented today at The International Liver Congress™ 2015 shows that by using genomic analyses to understand how and when carcinogenic mutations occur in patients with hepatocellular carcinoma (HCC), it is possible … read more
Share this page: Share on TwitterShare on FacebookShare on LinkedIn+1Share via email

Combination therapy offers new hope for difficult-to-treat patients with chronic hepatitis C

Preliminary results from the SOLAR 2 trial show that ledipasvir/sofosbuvir in combination with ribavirin is safe and effective in patients with decompensated liver disease or who have undergone liver transplantation April 23, 2015, Vienna, Austria: Results presented today at The International Liver Congress™ 2015 show that the use of the fixed-dose combination of ledipasvir/sofosbuvir (LDV/SOF) … read more
Share this page: Share on TwitterShare on FacebookShare on LinkedIn+1Share via email

New survey shows that half of people with hepatitis suffer from discrimination

Findings reveal the extent to which stigma and discrimination affect those living with viral hepatitis April 23, 2015, Vienna, Austria: As many as half of people infected with viral hepatitis have suffered discrimination and one-quarter admit that family members have avoided physical contact with them after finding out they had the infection. A shocking patient … read more
Share this page: Share on TwitterShare on FacebookShare on LinkedIn+1Share via email

Diabetes drug shows promise in the treatment of non-alcoholic steatohepatitis

In a randomised controlled trial, liraglutide met the primary endpoint of histological clearance of non-alcoholic steatohepatitis, and a reduction in progression of fibrosis April 23, 2015, Vienna, Austria: A drug approved to treat type 2 diabetes could prove to be a powerful new treatment option for non-alcoholic steatohepatitis (NASH), according to research presented today at … read more
Share this page: Share on TwitterShare on FacebookShare on LinkedIn+1Share via email

Pooled analysis confirms vitamin E as a treatment for non-alcoholic steatohepatitis

Study found that vitamin E is a safe and effective treatment for both adults and children April 23, 2015, Vienna, Austria: Results revealed today at The International Liver Congress™ 2015 show that vitamin E (d-alpha-tocopherol) is an effective treatment for non-alcoholic steatohepatitis (NASH). NASH occurs when the liver becomes inflamed due to the accumulation of … read more
Share this page: Share on TwitterShare on FacebookShare on LinkedIn+1Share via email

Daclatasvir-sofosbuvir combination is highly effective and well tolerated in patients with hepatitis C and HIV co-infection

Results from ALLY-2 confirm drug was well tolerated and effective across genotypes 1-4 April 23, 2015, Vienna, Austria: Phase III results revealed today at The International Liver Congress™ 2015 show that once-daily treatment with daclatasvir (DCV) plus sofosbuvir (SOF) resulted in an overall 97% sustained virologic response (SVR) at 12 weeks post-treatment in patients with … read more
Share this page: Share on TwitterShare on FacebookShare on LinkedIn+1Share via email

Herbal remedy derived from milk thistle demonstrates efficacy in non-alcoholic steatohepatitis

Silymarin results in resolution of non-alcoholic steatohepatitis and improvement in fibrosis April 23, 2015, Vienna, Austria: Results from a double-blind, placebo-controlled study of silymarin, which is derived from the milk thistle plant, have shown that this herbal remedy may be a useful treatment option for non-alcoholic steatohepatitis (NASH). An interim analysis of the study, revealed … read more
Share this page: Share on TwitterShare on FacebookShare on LinkedIn+1Share via email

Preliminary results show Civacir® prevents recurrence of hepatitis C in liver transplant patients

Phase III data demonstrate prophylactic efficacy of Civacir® in patients who undergo antiviral therapy prior to transplantation April 23, 2015, Vienna, Austria: New data from an ongoing Phase III trial revealed today at The International Liver CongressTM 2015 show that the use of hepatitis C immune globulin (HCIG, Civacir®) can effectively prevent hepatitis C virus … read more
Share this page: Share on TwitterShare on FacebookShare on LinkedIn+1Share via email

All-oral, direct-acting antivirals show promise for hepatitis C and HIV co-infected, cirrhotic patients

Latest results show sofosbuvir-based combinations are effective and well tolerated in difficult-to-treat patients April 23, 2015, Vienna, Austria: A new study revealed today at The International Liver CongressTM 2015 shows that sofosbuvir (SOF)-based regimens are effective and well tolerated in hepatitis C and HIV co-infected, cirrhotic patients. Sustained virologic response at 4 weeks (SVR4) was … read more
Share this page: Share on TwitterShare on FacebookShare on LinkedIn+1Share via email

Many European countries ill-prepared to prevent and control the spread of viral hepatitis

Comprehensive national strategies are urgently needed to manage the growing burden of disease April 23, 2015, Vienna, Austria: Many countries in the World Health Organization (WHO) European Region are facing limitations in conducting chronic viral hepatitis disease surveillance, assessing the burden of disease and measuring the impact of interventions, according to results revealed today at … read more
Share this page: Share on TwitterShare on FacebookShare on LinkedIn+1Share via email

Global expansion of hepatitis vaccination and treatment is needed to make progress towards elimination of hepatitis B

Expansion of existing interventions could prevent 13 million deaths due to hepatitis B April 23, 2015, Vienna, Austria: Results revealed today at The International Liver Congress™ 2015 demonstrate current treatment and prevention programmes need to be scaled up in order to make elimination of hepatitis B virus (HBV) possible. The study conducted by Imperial College … read more
Share this page: Share on TwitterShare on FacebookShare on LinkedIn+1Share via email

Delaying treatment for hepatitis C puts patients’ lives at risk

Analyses from the Veterans Administration healthcare system in the USA highlights dangers of delaying treatment to save costs April 23, 2015, Vienna, Austria: Data revealed today at The International Liver Congress™ 2015 highlights the impact of delaying treatment for the hepatitis C virus (HCV). Researchers found that treatment delays have a serious detrimental effect on … read more
Share this page: Share on TwitterShare on FacebookShare on LinkedIn+1Share via email

All-oral, direct-acting antiviral treatment options for hepatitis C proven to be highly effective and well tolerated in patients with decompensated cirrhosis

Interim report from the HCV-TARGET real world experience April 23, 2015, Vienna, Austria: Interim data presented today at The International Liver CongressTM 2015 from the HCV-TARGET study show that all-oral, direct-acting antiviral therapy for hepatitis C (HCV) is well tolerated and highly effective in patients with decompensated cirrhosis. Sustained virologic response (SVR) at 4 weeks … read more
Share this page: Share on TwitterShare on FacebookShare on LinkedIn+1Share via email

During The International Liver Congress 2015™, this section will regularly be updated with the latest congress news.